Company
IXICO PLC
LON:IXI
IXICO is no ordinary Imaging Contract Research Organisation (iCRO). By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and a 20-year track record as an end-to-end iCRO. IXICO addresses the complex biomarker challenges associated with neurodegenerative conditions, expertly managing and analysing neuroimaging clinical trials in areas such as Alzheimer’s, Parkinson’s, Huntington's and other rare diseases.
263 stories · page 3 of 14
Archive
Small Cap Feast - IXICO, and more...
23rd May 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners: No joiners today.Leavers: Hyve Group (HYVE) has left the Premium Segment of the London Stock Exchange.What’s
IXICO predicts return to sales growth from next year
Revenues will grow by at least 10% in 2024 said the statment
IXICO sees FY23 revenue in line with expectations; boosted by Alzheimer's developments
The year-end order book of £16mln reflected the signing of £12.6mln worth of new contracts over the year